by shibi76 | Jul 29, 2024 | Uncategorised
Cancer remains a formidable adversary, constantly evolving to evade our efforts at eradication. The mechanisms that enable tumor cells to thrive—ranging from genetic mutations and chromosomal instabilities to alterations in key enzymes and proteins—can be targeted for...
by shibi76 | Jul 10, 2024 | Uncategorised
New Cancer Drugs Approved in 2023 In 2023, the U.S. Food and Drug Administration (FDA) approved several new cancer drugs that offer promising treatment options for patients. Here are some of the key cancer drug approvals from the past year: Pembrolizumab Plus...
by shibi76 | Jul 10, 2024 | Uncategorised
FDA Approves Belzutifan for Advanced Renal Cell Carcinoma The FDA has approved belzutifan (Welireg) for the treatment of adult patients with advanced renal cell carcinoma (RCC) who have received prior therapy with a PD-1/PD-L1 inhibitor and a VEGF-TKI[1][2][4][5]....
by shibi76 | May 12, 2024 | Uncategorised
FDA Approves Mirvetuximab Soravtansine-gynx for Ovarian Cancer On March 22, 2024, the FDA approved mirvetuximab soravtansine-gynx (Elahere) for adult patients with FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who...
